Reported 1 day ago
RBC Capital has cut its price target for Xencor, Inc. (NASDAQ:XNCR) from $32 to $15 but maintains an Outperform rating, believing the current share price underrepresents the company's value. Despite recognizing challenges, including limited data and fewer growth drivers outside oncology, RBC highlighted strong prospects in areas like XmAb942 for inflammatory bowel diseases and its immunology program. The firm suggests that, even with the reduced target, Xencor remains a buy.
Source: YAHOO